Kato, Shumei <br/><br/>
Phase I study of the combination of crizotinib (as a MET inhibitor) and dasatinib (as a c-SRC inhibitor) in patients with advanced cancer.  [electronic resource] 

 -  Investigational new drugs  06 2018 
 - 416-423 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural 
<br/><br/><label>ISSN: </label>1573-0646 
<br/><br/><label>Standard No.: </label>10.1007/s10637-017-0513-5  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Antineoplastic Agents--adverse effects<br/>Antineoplastic Combined Chemotherapy Protocols--adverse effects<br/>Crizotinib--adverse effects<br/>Dasatinib--adverse effects<br/>Female<br/>Humans<br/>Male<br/>Middle Aged<br/>Neoplasm Staging<br/>Neoplasms--drug therapy<br/>Protein Kinase Inhibitors--adverse effects<br/>Treatment Outcome